CHRS
Price
$1.23
Change
+$0.10 (+8.85%)
Updated
Aug 22 closing price
Capitalization
142.96M
78 days until earnings call
SLXN
Price
$7.18
Change
+$0.38 (+5.59%)
Updated
Aug 22 closing price
Capitalization
5.25M
Interact to see
Advertisement

CHRS vs SLXN

Header iconCHRS vs SLXN Comparison
Open Charts CHRS vs SLXNBanner chart's image
Coherus Oncology
Price$1.23
Change+$0.10 (+8.85%)
Volume$2.57M
Capitalization142.96M
Silexion Therapeutics
Price$7.18
Change+$0.38 (+5.59%)
Volume$26.38K
Capitalization5.25M
CHRS vs SLXN Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. SLXN commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and SLXN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (CHRS: $1.23 vs. SLXN: $7.18)
Brand notoriety: CHRS and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 183% vs. SLXN: 29%
Market capitalization -- CHRS: $142.96M vs. SLXN: $5.25M
CHRS [@Biotechnology] is valued at $142.96M. SLXN’s [@Biotechnology] market capitalization is $5.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 2 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 2 green, 3 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • SLXN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than SLXN.

Price Growth

CHRS (@Biotechnology) experienced а +17.14% price change this week, while SLXN (@Biotechnology) price change was -0.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($143M) has a higher market cap than SLXN($5.25M). CHRS YTD gains are higher at: -10.870 vs. SLXN (-76.186). CHRS has higher annual earnings (EBITDA): 88.2M vs. SLXN (-17.81M). CHRS has more cash in the bank: 238M vs. SLXN (3.47M). SLXN has less debt than CHRS: SLXN (3.7M) vs CHRS (41M). CHRS has higher revenues than SLXN: CHRS (272M) vs SLXN (0).
CHRSSLXNCHRS / SLXN
Capitalization143M5.25M2,722%
EBITDA88.2M-17.81M-495%
Gain YTD-10.870-76.18614%
P/E Ratio2.32N/A-
Revenue272M0-
Total Cash238M3.47M6,867%
Total Debt41M3.7M1,109%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
5
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSSLXN
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
55%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
40%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
22%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
20%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
52%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 27 days ago
51%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBLOF0.95N/A
N/A
Public Bank Ltd
PHJMF0.03N/A
N/A
PT Hanjaya Mandala Sampoerna Terbuka
VDEVF35.66N/A
N/A
Van de Velde NV
QQREF0.06N/A
N/A
Quebec Rare Earth Elements Corp.
CONXF0.50-0.01
-2.82%
NICKEL 28 CAP CORP.

SLXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
+5.59%
IMA - SLXN
63%
Loosely correlated
+1.07%
CELC - SLXN
50%
Loosely correlated
+4.05%
MRSN - SLXN
43%
Loosely correlated
-4.44%
CHRS - SLXN
26%
Poorly correlated
+8.85%
QSI - SLXN
25%
Poorly correlated
+2.70%
More